Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial

Phillip H. Kuo; Taylor Benson; Richard Messmann; Michael Groaning

doi:10.2967/jnumed.121.263638

Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial

Phillip H. Kuo, Taylor Benson, Richard Messmann, Michael Groaning

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	816-818
Number of pages	3
Journal	Journal of Nuclear Medicine
Volume	63
Issue number	6
DOIs	https://doi.org/10.2967/jnumed.121.263638
State	Published - Jun 1 2022

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.2967/jnumed.121.263638

Cite this

@article{4257ab2a919f4a40b753e67cc5d520e1,

title = "Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial",

author = "Kuo, {Phillip H.} and Taylor Benson and Richard Messmann and Michael Groaning",

note = "Funding Information: Phillip Kuo is an employee of Invicro. He is a consultant or speaker for Amgen, Eisai, Endocyte, GE Healthcare, Novartis, Invicro, Bayer, Chimerix, Fusion Pharma, and UroToday. He is a recipient of research grants from Blue Earth Diagnostics and GE Healthcare. Richard Messmann is an employee of Novartis and previously of Endocyte. Taylor Benson is an employee of Novartis and previously of Endocyte. Michael Groaning is an employee of Amgen and previously of Endocyte and Novartis. No other potential conflict of interest relevant to this article was reported.",

year = "2022",

month = jun,

day = "1",

doi = "10.2967/jnumed.121.263638",

language = "English (US)",

volume = "63",

pages = "816--818",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "6",

}

TY - JOUR

T1 - Why We Did What We Did

T2 - PSMA PET/CT Selection Criteria for the VISION Trial

AU - Kuo, Phillip H.

AU - Benson, Taylor

AU - Messmann, Richard

AU - Groaning, Michael

N1 - Funding Information: Phillip Kuo is an employee of Invicro. He is a consultant or speaker for Amgen, Eisai, Endocyte, GE Healthcare, Novartis, Invicro, Bayer, Chimerix, Fusion Pharma, and UroToday. He is a recipient of research grants from Blue Earth Diagnostics and GE Healthcare. Richard Messmann is an employee of Novartis and previously of Endocyte. Taylor Benson is an employee of Novartis and previously of Endocyte. Michael Groaning is an employee of Amgen and previously of Endocyte and Novartis. No other potential conflict of interest relevant to this article was reported.

PY - 2022/6/1

Y1 - 2022/6/1

UR - http://www.scopus.com/inward/record.url?scp=85130282474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130282474&partnerID=8YFLogxK

U2 - 10.2967/jnumed.121.263638

DO - 10.2967/jnumed.121.263638

M3 - Editorial

C2 - 35086895

AN - SCOPUS:85130282474

SN - 0161-5505

VL - 63

SP - 816

EP - 818

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 6

ER -

Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this